JPJean-Louis Pujol

Jean-Louis Pujol

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jean-Louis Pujol has a total of 183 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 October 2007
      • Vol. 24, 6S16-21

    [Smoking cessation in patients with lung cancer].

    by X Quantin, A Stoebner-Delbarre, P Guichenez, J-L Pujol

    Smoking cessation is an important part of the management of patients with lung cancer. Continued smoking has been found to diminish treatment efficacy, to exacerbate side effects and to have a detrimental effect on survival. Smoking increases postoperative pulmonary complications and tolerance and efficacy of medical treatment (chemotherapy, targeted therapy, radiotherapy) are diminished. Moreover, the quality of life of current smokers is lower and the risk of a second primary malignancy is increased. Hospitalization is a good opportunity to propose smoking cessation. Clinical practice guidelines recommend the use of combined behavioral and pharmacological therapies. The efficacy of smoking cessation programs for cancer patients has been demonstrated. There is a clear dose-response relationship between number of contacts, intensity level of person-to-person contact and total amount of contact time. Multidisciplinary approaches increase abstinence rates. First line phamacotherapies (nicotine replacement therapy and sustained-release antidepressant bupropion) have been found to be safe and effective. Varenicline is a new drug for smoking cessation but it remains to be evaluated in oncology patients.

    • 1 September 2006
      • Vol. 23, 10S5-10S6

    [Mediteranean environment and thoracic pathology].

    by P Godard, R Chiron, J-L Pujol, P Chanez, P Demoly, R Clavel, X Quantin, J Bousquet, C Prefaut

    • 1 June 2006
      • Vol. 1  (5) , 417-24

    Gefitinib (IRESSA) with vinorelbine or vinorelbine/cisplatin for chemotherapy-naive non-small cell lung cancer patients.

    by Jean-Louis Pujol, Patrick Viens, Paul Rebattu, Scott A Laurie, Ronald Feld, Anne Deneulin, Abderrahim Fandi

    This phase I study assessed the safety, pharmacokinetics, and efficacy of gefitinib (IRESSA) combined with vinorelbine or vinorelbine/cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC). Patients received gefitinib 250 mg/day and vinorelbine (group A; n = 6) or vinorelbine/cisplatin (group B; n = 8). An additional set of group B patients (n = 9) received gefitinib 500 mg/day with vinorelbine/cisplatin. Adverse events were consistent with individual treatments of gefitinib (mild reversible rash, diarrhea) and chemotherapy (asthenia, fever, nausea, vomiting, constipation), although there was a higher than expected incidence of Common Toxicity Criteria grade 3 or 4 hematologic adverse events, specifically febrile neutropenia and neutropenia. Pharmacokinetic data suggested that neither of the chemotherapy regimens affected steady-state exposure to gefitinib and also that steady-state gefitinib did not alter exposure to vinorelbine or cisplatin. Objective, durable antitumor activity was observed: five partial responses (one in group A; four in group B) and six patients with stable disease (all in group B). The safety data demonstrated that gefitinib with vinorelbine or vinorelbine/cisplatin resulted in severe myelosuppression leading to an unacceptable rate of febrile neutropenia. This study does not support the concurrent administration of gefitinib and vinorelbine, with or without cisplatin, as a valid treatment for advanced NSCLC.


  • Gefitinib (IRESSA) with Vinorelbine or Vinorelbine/Cisplatin for Chemotherapy-Naive Non-small Cell Lung Cancer Patients

    by Jean-Louis Pujol, Patrick Viens, Paul Rebattu, Scott A. Laurie, Ronald Feld, Anne Deneulin, Abderrahim Fandi


  • Should chemotherapy (Cx) for advanced non-small cell lung cancer (NSCLC) be platinum-based? A literature-based meta-analysis of randomized trials

    by F. Barlesi, J.-L. Pujol, J.-P. Daurès

    7213 Background: Platinum-based Cx are world-wide accepted regimens in the treatment of advanced NSCLC. Third generation anti-cancer agents share a better efficacy/toxicity profile when compared with the older ones. Therefore, several recent studies have tested the hypothesis that non-platinum containing regimens can be an alternative therapy to the classical platinum-based Cx in advanced NSCLC. Methods: We made a meta-analysis of published data reporting trials randomizing a platinum-containing Cx versus a doublet platinum-free Cx including at least one third generation anti-cancer agent namely, vinorelbine (V), docetaxel (D), gemcitabine (G), and paclitaxel (P) in order to determine possible differences in survival, response and toxicity. Fourteen trials have been identified in the medical literature (5943 randomized patients). The experimental arms were GV (four trials), GD or GP (seven trials), G - epidoxorubicin (one trial), VP (one trial), and G - ifosfamide (one trial). The comparator consisted of a doublet Cx of a platinum compound plus a third generation drug in all studies except two where the comparator was a triplet Cx. Updated data were available for all studies but one. The Peto and Yusuf method was used in order to generate the odds ratios (OR) of reduction in the risk of death at one year for patients receiving a platinum-based Cx. Results: A statistical heterogeneity was detected when the whole trials was considered (chi2 test: 21.05; p = 0.049). This heterogeneity has been identified as belonging to the two studies that used triplets as the standard arms. When the analysis was restricted to the eleven studies that used a well-recognised platinum-based doublet as standard, there was no statistical heterogeneity (chi2 test: 16.6; p = 0.084). Patients treated with a cisplatin-containing regimen benefited from a significant reduction of risk of death at one year with OR=0.88, 95% CI [0.78 - 0.99]; p = 0.044. Conclusions: A platinum-containing regimen induced a significant reduction in the risk of death when compared with platinum-free regimen. A complete analysis of the risk of toxic-death, toxicity and response will be presented. No significant financial relationships to disclose.


  • Open Access

    Gemcitabine–docetaxel versus cisplatin–vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin

    by J.-L. Pujol, J.-L. Breton, R. Gervais, P. Rebattu, A. Depierre, J.-F. Morère, B. Milleron, D. Debieuvre, D. Castéra, P.-J. Souquet, et al.

    Background: This multicenter, randomized, phase III study compared the efficacy, including progression-free survival (PFS), and safety of gemcitabine–docetaxel (GD) combination versus cisplatin–vinorelbine (CV) in the treatment of advanced non-small-cell lung cancer (NSCLC). Patients and methods: Chemonaïve patients with stage IIIB or IV NSCLC were treated with GD (gemcitabine 1000 mg/m2 days 1 and 8 plus docetaxel 85 mg/m2 day 8, every 3 weeks for eight cycles) or CV (cisplatin 100 mg/m2 day 1 plus vinorelbine 30 mg/m2, days 1, 8, 15 and 22, every 4 weeks for six cycles). Results: A total of 311 patients were enrolled (155 GD and 156 CV). Neither PFS nor overall survival differed significantly between the two arms (median PFS 4.2 and 4 months; median survival 11.1 and 9.6 months; 1-year survival 46% and 42%, for GD and CV, respectively). For the GD arm compared with the CV arm, the hazard ratio for PFS was 1.04 [95% confidence interval (CI) 0.83–1.32], and for overall survival, it was 0.90 (95% CI 0.70–1.16). Objective response rates did not differ significantly (31% for GD, 35.9% for CV). Myelosupression, emesis and frequency of febrile neutropenia were less pronounced on the GD arm, whereas fluid retention and pulmonary events were more pronounced. The CV arm experienced a higher number of serious adverse events and a lower compliance with the protocol. There was no quality of life (QoL) difference between arms. Median time to definite impairment of health-related QoL was 153 and 168 days in GD and CV arms, respectively. Conclusions: There was no advantage in PFS with GD compared with CV; however, the CV regimen had higher rate of toxic events, mainly myelosuppression. The herein, non-platinum-containing regimen could be considered as a rational alternative to the cisplatin-based doublet.


    • 1 November 2004
      • Vol. 60, 3S60-7

    [Do combinations without cisplatin represent an alternative to conventional chemotherapy in non-small cell lung cancers?].

    by J-L Pujol, W Jacot, J-L Breton, R Gervais, X Quantin, P Rebattu

    Chemotherapy of advanced non-small cell lung cancers is based on cisplatin, which prolongs survival. However, the high toxicity of double-type combinations including cisplatin warrants the search for alternatives. New anti-cancer cytotoxic agents exhibit improved efficacy-toxicity ratio. Bitherapy, without cisplatin and with new molecules, provides hope of improvement in survival without deterioration in quality of life. Several randomised trials, already published or presented with mature results, suggest that certain bitherapies with new cytostatic agents are an alternative to the classical cisplatin-based bitherapies. The recent modifications in the guidelines of the American Association of Clinical Oncology take into account these recent results by admitting that "chemotherapy without cisplatin can be used as an alternative to the first-line platin-based chemotherapies". This brief review of the literature underlines the methodological questions raised by the publication of randomised studies essentially assessing gemcitabine-vinorelbine or gemcitabine-taxane combinations, by confronting them with either mono-chemotherapies or reference chemotherapy based on cisplatin. The assessment criteria selected in such studies are discussed.

  • Open Access

    Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer

    by W Jacot, J-L Pujol, J-M Boher, P-J Lamy

    This retrospective study aimed at evaluating the prognostic impact of high serum levels of either the HER-2 extracellular domain (ECD) or the epidermal growth factor receptor (EGFR) ECD measured using two specific ELISAs in 221 patients with non-small-cell lung cancer (NSCLC) receiving conventional therapy and 41 nonmalignant pulmonary diseases patients. It was not possible to discriminate between lung cancer and benign lung disease owing to the lack of sensitivity–specificity relationship of HER-2 and EGFR ECD levels. Neither HER-2 nor EGFR ECD specific levels were associated with a particular prognosis of NSCLC patients receiving conventional therapy.